共 41 条
[41]
Zubrod CG., 1960, J CHRONDIS, V11, P7, DOI [DOI 10.1016/0021-9681(60)90137-5, 10.1016/0021-9681, DOI 10.1016/0021-9681]
Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC
被引：4
作者：
Jiang, Wei
[1
]
Zeng, Aiping
[1
]
Ning, Ruiling
[1
]
Zhao, Wenhua
[1
]
Su, Cuiyun
[1
]
Wang, Huilin
[1
]
Zhou, Shaozhang
[1
]
Yu, Qitao
[1
]
机构：
[1] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Resp Oncol, 71 Hedi Rd, Nanning 530021, Guangxi, Peoples R China
关键词：
NSCLC;
tumor genetic alteration profiling;
NGS;
chemotherapy;
EGFR-TKI;
CELL LUNG-CANCER;
CISPLATIN PLUS GEMCITABINE;
OPEN-LABEL;
1ST-LINE TREATMENT;
PHASE-III;
GEFITINIB;
MUTATION;
OSIMERTINIB;
MULTICENTER;
HETEROGENEITY;
D O I：
10.3892/ol.2020.11502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Previous studies have suggested that a variety of tumor driver genetic alterations affected the treatment efficacy of chemotherapy and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). The present study aimed to investigate the association between the tumor genetic alteration landscape and the treatment outcome of first-line chemotherapy and EGFR-TKIs in advanced NSCLC. A total of 94 patients with advanced NSCLC were recruited. All patients received first-line chemotherapy and/or EGFR-TKIs (either first- or second-generation EGFR-TKI, or third-generation EGFR-TKI) alone or sequentially. Prior to chemotherapy and/or EGFR-TKI treatment, plasma, effusion and/or tumor tissues from the included patients were subjected to next-generation sequencing, targeting 59 genes. The results indicated that the positive genetic alteration status prior to first-line chemotherapy was associated with prolonged progression-free survival (PFS) time compared with the negative status [9.1 vs. 4.0 months; hazard ratio (HR)=6.68; 95% CI, 2.25-19.82; P=0.001). Furthermore, patients with EGFR activating mutation harboring concomitant alterations exhibited a shorter PFS (11.1 vs. 7.4 months; HR=2.14; 95% CI, 1.03-4.44; P=0.04) and overall survival (OS) time [not reached (NR) vs. 32.8 months; HR=4.30; 95% CI, 1.41-13.16; P=0.01] than those without concomitant alterations, with first- and second-generation EGFR-TKI treatment. Similarly, patients with T79M mutation harboring concomitant alterations exhibited a shorter PFS (15.6 vs. 3.6 months; HR=9.48; 95% CI, 2.29-39.28; P=0.002) and OS time (NR vs. 32.8 months; HR=4.85; 95% CI, 1.16-20.29; P=0.03) with osimertinib treatment. Taken together, the results demonstrated that positive genetic alteration status predicted greater efficacy of first-line chemotherapy, while concomitant genetic alterations were associated with poor treatment outcome for first- or second-generation EGFR-TKI and third-generation EGFR-TKI treatment.
引用
收藏
页码：3859 / 3870
页数：12
相关论文